Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash & Equivalents (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Cash & Equivalents data on record, last reported at $216.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 12.57% year-over-year to $216.3 million; the TTM value through Sep 2025 reached $216.3 million, up 12.57%, while the annual FY2024 figure was $151.6 million, 5.07% up from the prior year.
  • Cash & Equivalents reached $216.3 million in Q3 2025 per AMPH's latest filing, up from $187.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $266.8 million in Q3 2023 and bottomed at $101.6 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $165.8 million, with a median of $166.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 79.16% in 2021, then fell 27.99% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $126.4 million in 2021, then rose by 23.54% to $156.1 million in 2022, then fell by 7.56% to $144.3 million in 2023, then grew by 5.07% to $151.6 million in 2024, then surged by 42.65% to $216.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $216.3 million in Q3 2025, $187.7 million in Q2 2025, and $182.8 million in Q1 2025.